Drug Database · Clinicians

Naproxen + Omeprazole

Brands (1) NaprotectShow all

Non-steroidal anti-inflammatory drug (NSAID)/ proton pump inhibitor PH FDA category
Fixed-dose combination.

Rx · Prescription drug1 PH product
Dispensing: Prescription (Rx) Last updated: Audience: Licensed health professionals
US label not yet available for this generic. Check the Philippine package insert (linked in the products table where the FDA has published one).

Component information

No US or EU label exists for this exact combination, so information is shown for each component.

  • Use: rheumatoid arthritis US FDA label

    Kidney dosing: Naproxen (single-agent)
    Show full dosing details
    CrCl ≥60 mL/min
    Usual: naproxen 250 to 500 mg twice daily, or naproxen sodium 275 to 550 mg twice daily; lowest effective dose, shortest duration (label).
    CrCl 30–59 mL/min
    No label dose change at CrCl ≥30. Monitor creatinine, potassium and blood pressure; avoid volume depletion and the ACE inhibitor or ARB plus diuretic combination (label 5.6). Acute gout in CKD: low-dose colchicine or glucocorticoids are preferred over NSAIDs (KDIGO 2024 PP 3.14.3).
    CrCl 15–29 mL/min
    Not recommended at CrCl <30 mL/min (moderate to severe and severe impairment; label 8.7). Naproxen metabolites accumulate in kidney failure. Acute gout in CKD: low-dose colchicine or glucocorticoids are preferred over NSAIDs (KDIGO 2024 PP 3.14.3).
    CrCl <15 mL/min (not on dialysis)
    Not recommended at CrCl <30 mL/min (moderate to severe and severe impairment; label 8.7). Naproxen metabolites accumulate in kidney failure. Acute gout in CKD: low-dose colchicine or glucocorticoids are preferred over NSAIDs (KDIGO 2024 PP 3.14.3).
    Hemodialysis (intermittent)
    Not recommended (CrCl <30; label). NSAIDs may hasten loss of residual kidney function.
    Peritoneal dialysis
    Not recommended (CrCl <30; label). NSAIDs may hasten loss of residual kidney function.
    CRRT
    Avoid: NSAIDs can worsen acute kidney injury.
    • Dialyzable? Unlikely: hemodialysis may not be useful because of high protein binding (over 99%; label 10).
    • Monitoring Creatinine, potassium and blood pressure in CKD, heart failure, liver disease, dehydration or with ACE inhibitors, ARBs or diuretics. Naproxen sodium contains sodium (about 2 mEq per 500 mg naproxen).

    From the Naproxen monograph (renalcarematters.com, reviewed).

  • Use: Treatment of active duodenal ulcer in adults US FDA label

Note: Fixed-dose combinations may not allow the dose changes advised for each component; check the strength and use the single agents if a component needs adjusting.

Dosing: Altered kidney function

No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.

Kidney dosing for each component (single-agent) is shown under Component information.

Kidney-specific guidance from renalcarematters.com: in preparation.

Dosage forms

Philippines

  • Capsule: 275 mg/10 mg

Registered products in the Philippines

1 product registered with the Food and Drug Administration (FDA) Philippines list Naproxen + Omeprazole as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.

Verify on PH FDA portal

Philippine FDA-registered products for Naproxen + Omeprazole
Package insert
NaprotectNaproxen Sodium + Omeprazole
275mg/ 10mg CapsuleAluminum Flex Foil Strip x 6's (Box of 60's)
Rx
Amherst Laboratories, Inc.Philippines
Trader: UNILAB, Inc.
DRP-11165
Feb 15, 2027

Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.

Formulary and pricing (Philippines)

Check availability

Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.

References

  1. Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph

This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.

For health professionals. This page is a reference compiled from public regulatory sources for licensed health professionals in the Philippines. Verify every product detail against the current Philippine package insert and the FDA Philippines registration record. Information here is not a substitute for clinical judgment and does not replace the prescribing information approved for the specific product you dispense or prescribe.

Last updated: .